Vesper Medical raises $37mm in second funding round

Vesper Medical Inc. (devices for minimally invasive peripheral vascular procedures) raised $37mm in what appears to be its Series B financing led by Vensana Capital and Gilde Healthcare, which were joined by returning shareholders New Enterprise Associates and Quaker Partners. The company expects to receive funding from additional tranches based on key milestones. Vesper will use the proceeds to finish developing its Duo venous stent system and submit the PMA application to the FDA. Additional money will help gain the CE Mark for Vesper Duo stents. On the same day, Intact Vascular Inc., which spun out Vesper and is also developing minimally invasive devices for peripheral vascular procedures, raised $25mm through its Series D financing in which Vensana, NEA, and Quaker also participated.